SR
Therapeutic Areas
Mapi Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Glatiramer Acetate Depot | Relapsing‑remitting Multiple Sclerosis | Phase 3 |
| Pregabalin ER | Neuropathic Pain / Epilepsy | Preclinical |
| GLP‑1 Peptide Long‑Acting Injectable | Metabolic Disease | Preclinical |
| Buspirone ER | Anxiety | Preclinical |
| Paliperidone Depot | Schizophrenia | Preclinical |
| Aripiprazole Depot | Schizophrenia | Preclinical |
Leadership Team at Mapi Pharma
EM
Ehud Marom
Chairman & CEO
UD
Uri Danon
Executive VP
IZ
Irit Zalayet
VP Finance
AM
Alex Mogle
VP Corporate Development
LP
Laura Popper, M.D.
VP Clinical Development
NB
Nadav Bleich Kimelman, DMD, Ph.D.
VP Pharmaceutical Development
OM
Oren Milani
Head of Quality